System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Massimo Breccia is an expert in Hematology at Policlinico Umberto I (Italy). As of October 2026, ScienceLeadR ranks Massimo Breccia in the top 1% of experts worldwide for Leukemia, Hematologic Neoplasms and Anemia. Massimo Breccia has authored 1,017 publications, the most recent in 2026, and is an investigator in 40 clinical trials, 16 of them ongoing. SLR score: 4,205 (community average: 125). How the SLR is computed.

LeadR Profile

Massimo Breccia Policlinico Umberto I Italy
4 205 ScienceLeadR Reputation 4205

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Sapienza University of Rome

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1017

Citations

Citations: 18 044 1st author: 269 Last author: 122 Unique author: 15

Main journals

Blood 256
Leuk Res 91
Ann Hematol 62
Haematologica 55
Leuk Lymphoma 46

Best Journals

N Engl J Med 4
J Clin Oncol 3
Lancet Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.
PMID 42608172 — hematology, azoles		Br J Haematol20261
Kinetic BCR::ABL1 reduction by transcript types in frontline CML treatment: a GIMEMA LabNet CML network survey.
PMID 42866683 — therapeutics		Blood Neoplasia20260
Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia.
PMID 42867330 — leukemia, promyelocytic, acute, leukemia, drug therapy, therapeutics, tretinoin		Expert Opin Pharmacother20260
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.
PMID 42846649 — cells, therapeutics, janus kinase inhibitors, primary myelofibrosis		Onco Targets Ther20260
Congenital Hemophilia-A With High-Titer Inhibitor and Essential Thrombocythemia: A Rare Coexistence.
PMID 42723505 — thrombocythemia, essential, thrombocytosis, hemophilia a		Haemophilia20260

Clinical Studies 40

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 3 16
N/A 13
Phase 2 8
Phase 1/Phase 2 2
Phase 1 1

By status:

Completed 14
Recruiting 13
Active not recruiting 5
Unknown 5
Not yet recruiting 2
Terminated 1

By type:

Interventional 28
Observational 12

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 0
multicentricup10 34

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

16 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower risk MDS in ESA na ve adults who require RBC transfusions
2025-523544-12-00 — cells, epoetin alfa, myelodysplastic syndromes, safety, erythrocytes, blood, erythrocyte transfusion, anemia, neoplasms, blood cells, therapeutics		Phase 3Recruiting2026
A Phase I II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA MED)
2024-515252-20-00 — safety, multiple chronic conditions, janus kinase inhibitors, primary myelofibrosis		Phase 1/Phase 2Recruiting2025
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy
2024-512753-24-00 — genes, leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, chemotherapy		Phase 3Not yet recruiting2025
Efficacy of Asciminib in Real world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines
NCT07640750 — genes, abl, leukemia, leukemia, myeloid, chronic-phase, leukemia, myeloid, leukemia, myelogenous, chronic, bcr-abl positive		N/ANot yet recruiting2026
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161 — injections, safety, anemia, pharmaceutical preparations, drug therapy, therapeutics, primary myelofibrosis		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS